XOMA Stock Risk & Deep Value Analysis

XOMA Royalty Corporation has undergone a transformative pivot from a traditional, cash-burning biotech developer to a lean, pure-play royalty aggregator. This significantly alters its risk-reward profile. The company now boasts a high-margin, scalable business model focused on acquiring and managing diverse royalty streams from successful pharmaceutical products. Key assets like VOQUEZNA (vonoprazan) in Japan are generating growing revenues, with potential for further expansion and additional pipeline assets to mature. While still a small-cap, its strong cash flow generation and diversified portfolio offer a compelling, albeit speculative, 10x growth pathway if key underlying products achieve significant market penetration or if XOMA continues to acquire high-value royalty assets efficiently. Execution risk lies in the commercial success of partner products and the savvy acquisition of new royalty streams.